CD38 and chronic myelogenous leukemia, BCR-ABL1 positive: As a first approach, we performed a global comparison of the gene expression profiles from the four cell populations analyzed, that is, CD34+ CD38−Lin− (enriched for HSCs) and CD34+ CD38+Lin− (enriched for HPCs) cells from both, hematologically normal subjects and CML patients.